Alzamend Neuro Presents Preliminary AL001 Brain Connectivity Findings

Alzamend Neuro presented preliminary fMRI findings comparing AL001 with lithium carbonate in six healthy participants. The study showed descriptive differences in brain connectivity, but no changes survived statistical correction. The company noted the small sample size and need for further study. The findings were presented at the Society for Neuroscience annual meeting on November 18, 2026, according to an SEC filing.

Original reporting
Published Nov 18, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alzamend Neuro Presents Preliminary AL001 Brain Connectivity Findings — source image
Decision brief

The 30-second read

$ALZNNeutralLow
01

Why it matters

Because the results are exploratory and do not survive FDR correction, the disclosure is more supportive of continued research than of a definitive efficacy signal.

02

Market read

Traders may treat this as an early biomarker update, but the lack of statistically robust connectivity changes likely limits immediate re-rating catalysts.

03

What to watch

The article does not state effect sizes, imaging endpoints beyond connectivity, or whether the study was powered for these analyses, limiting interpretation of biological relevance.

Relevance 4/10Novelty 5/10Timing: conference presentation dated Nov. 18, 2026

Background

The company presented preliminary resting-state fMRI connectivity findings for AL001 compared with lithium carbonate in healthy participants at the Society for Neuroscience annual meeting.

Company-level read

Ticker impact

$ALZNNeutralHigh confidence
Context

Alzamend Neuro (AL001) presented preliminary resting-state fMRI connectivity results versus lithium carbonate, with no connectivity changes surviving FDR correction.

Expected impact

Likely limited near-term upside as the data are explicitly preliminary and fail multiple-testing correction, reducing conviction.

Evidence & confidence

The article emphasizes small n=6, exploratory findings, and that no network-pair connectivity changes survived false discovery rate correction.

Market effects

Adds incremental clinical-development signal for neuroimaging biomarkers in CNS drug development, but without confirmatory statistics.

None indicated.

None indicated.

Counterpoint

Exploratory connectivity differences could still motivate protocol refinement or larger-cohort studies, which may be viewed positively by some biotech traders despite lack of FDR significance.

Key entities

  • Alzamend Neuro, Inc.

    Issuer presenting preliminary AL001 brain connectivity findings versus lithium carbonate.

  • AL001

    Investigational candidate evaluated in the resting-state fMRI study.

  • Lithium carbonate

    Standard-of-care comparator used in the study design.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.

$ELOXMed

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

Eloxx Pharmaceuticals (ELOX) published Phase 2a trial results in the Journal of Clinical Investigation, showing exaluren increased collagen IV production and improved kidney cell structure in patients with nonsense mutation Alport syndrome. The drug was well-tolerated. The company is conducting a Phase 2b study (EXACT) with topline data expected in mid-2027.